Comments
Drug firm Granules India today said it has received an Establishment Inspection Report (EIR) from the US health regulator for the OmniChem facility at Vizag, Andhra Pradesh.
The OmniChem facility is operated by a 50:50 joint venture of Granules India and Ajinimoto OmniChem N V, it said in a filing on BSE.
The United States Food and Drug Administration (USFDA) has issued an EIR for the company’s OmniChem facility, it added.
“This facility was inspected by the USFDA in December 2016 and there were seven observations during the inspection. The facility manufactures Active Pharmaceutical Ingredients (API) intermediates,” Granules India said.
Shares of Granules India were today trading at Rs 122 per scrip on the BSE, up 6.50 per cent from its previous close.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.